Skip to main content

MS news

Our news web pages include ground-breaking multiple sclerosis news and research from around the world. 

These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.

Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content.

Supporting you

We’re here to support you, whether you are awaiting a diagnosis of multiple sclerosis or have been living with the condition for years. 

Image of the MS-UK Helpline button graphic containing a link to the Helpline page

Image of the New Pathways magazine button graphic containing a link to the New Pathways magazine page


A study by scientists at The Scripps Research Institute (TSRI) has helped to de-mystify the molecular workings of the multiple sclerosis drug Tecfidera®. The drug is the most widely prescribed...

University of Maryland researchers have manipulated lymph nodes to “switch off” autoimmune attacks in diseases like multiple sclerosis while preserving healthy immune function. The treatment,...

Novartis recently announced positive results from the ACROSS study, which is assessing the clinical effect of Gilenya (fingolimod) in 10-year disability outcomes in people with relapsing-remitting...

A recent phase IV study showed that after one year, the majority of multiple sclerosis patients taking oral Gilenya (fingolimod) therapy stuck with their treatment, while a large proportion of...

A recent study showed that the clinical benefits offered by Ampyra (fampridine) in improving mobility among multiple sclerosis patients has clinical significance.

The results were shown in...

Physiotherapists can meet people with multiple sclerosis at a Chartered Society of Physiotherapy (CSP) hosted event to share ideas and discuss collaborating on research into better care.

...

European researchers are putting finishing touches on the first-ever clinical guideline for drug treatment of multiple sclerosis, with a preview presented at ECTRIMS in advance of its final...

A five-year study comparing the efficacy of different treatments for relapsing-remitting multiple sclerosis (RRMS) found that, in general, Lemtrada (alemtuzumab) and Tysabri (natalizumab) are more...

Merck recently presented new efficacy data from its three Phase 3 clinical trials, showing that a relatively short course of treatment with Cladribine tablets led to long-term reductions in...

Sanofi Genzyme presented positive results from its Phase 4 study into patient-reported assessments of Aubagio (teriflunomide), an approved oral treatment for relapsing forms of multiple sclerosis...

Pages

Live Chat Software by Click4Assistance UK